Vanguard Group
ALLO icon

Vanguard Group’s Allogene Therapeutics ALLO Stock Holding History

Vanguard Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$12.7M Buy
9,251,609
+230,839
+3% +$305K ﹤0.01% 2847
2025
Q3 		$11.2M Buy
9,020,770
+761,642
+9% +$908K ﹤0.01% 2924
2025
Q2 		$9.33M Buy
8,259,128
+191,575
+2% +$255K ﹤0.01% 2941
2025
Q1 		$11.8M Buy
8,067,553
+66,861
+0.8% +$126K ﹤0.01% 2756
2024
Q4 		$17M Sell
8,000,692
-327,007
-4% -$806K ﹤0.01% 2660
2024
Q3 		$23.3M Buy
8,327,699
+132,033
+2% +$352K ﹤0.01% 2518
2024
Q2 		$19.1M Sell
8,195,666
-11,898
-0.1% -$35.1K ﹤0.01% 2598
2024
Q1 		$36.7M Sell
8,207,564
-823,261
-9% -$3.44M ﹤0.01% 2300
2023
Q4 		$29M Sell
9,030,825
-1,556,979
-15% -$4.42M ﹤0.01% 2428
2023
Q3 		$33.6M Buy
10,587,804
+3,086,311
+41% +$13.5M ﹤0.01% 2319
2023
Q2 		$37.3M Buy
7,501,493
+196,157
+3% +$1.06M ﹤0.01% 2320
2023
Q1 		$36.1M Buy
7,305,336
+40,115
+0.6% +$257K ﹤0.01% 2324
2022
Q4 		$45.7M Buy
7,265,221
+102,139
+1% +$946K ﹤0.01% 2224
2022
Q3 		$77.4M Sell
7,163,082
-1,243,065
-15% -$16.9M ﹤0.01% 1950
2022
Q2 		$95.8M Buy
8,406,147
+1,652,167
+24% +$14.7M ﹤0.01% 1850
2022
Q1 		$61.5M Buy
6,753,980
+12,141
+0.2% +$126K ﹤0.01% 2203
2021
Q4 		$101M Buy
6,741,839
+46,119
+0.7% +$814K ﹤0.01% 1981
2021
Q3 		$172M Buy
6,695,720
+93,414
+1% +$2.22M ﹤0.01% 1692
2021
Q2 		$172M Buy
6,602,306
+645,613
+11% +$18.4M ﹤0.01% 1709
2021
Q1 		$210M Buy
5,956,693
+170,216
+3% +$5.74M 0.01% 1552
2020
Q4 		$146M Buy
5,786,477
+129,274
+2% +$4.21M ﹤0.01% 1641
2020
Q3 		$213M Sell
5,657,203
-224,111
-4% -$8.45M 0.01% 1240
2020
Q2 		$252M Buy
5,881,314
+1,781,863
+43% +$64.4M 0.01% 1128
2020
Q1 		$79.7M Buy
4,099,451
+151,158
+4% +$3.6M ﹤0.01% 1656
2019
Q4 		$103M Buy
3,948,293
+523
+0% +$14.4K ﹤0.01% 1738
2019
Q3 		$108M Buy
3,947,770
+504,590
+15% +$14.4M ﹤0.01% 1681
2019
Q2 		$92.4M Buy
3,443,180
+1,343,459
+64% +$37.4M ﹤0.01% 1794
2019
Q1 		$60.7M Buy
2,099,721
+53,392
+3% +$1.55M ﹤0.01% 1997
2018
Q4 		$55.1M Buy
+2,046,329
New +$54.4M ﹤0.01% 1982

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Group's ALLO Position: Q4 2025 in Review

Vanguard Group increased its Allogene Therapeutics (ALLO) stake by 2.6% in Q4 2025, buying an estimated $305K and bringing the position to 9,251,609 shares worth $12.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2847.

Vanguard Group first reported a position in ALLO in Q4 2018 and has held it in 29 quarters since. The position peaked at $252M in Q2 2020. 172 funds tracked by Wall St. Rank hold ALLO as of Q4 2025.

  • Vanguard Group held 9,251,609 shares of Allogene Therapeutics worth $12.7M as of Q4 2025.
  • Vanguard Group bought 230,839 Allogene Therapeutics shares in Q4 2025, an estimated $305K.
  • Allogene Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2847 holding.
  • Vanguard Group first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 29 quarters since.
  • Vanguard Group's Allogene Therapeutics position peaked at $252M in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.